Home Cell Therapies in Solid Tumors: A bright future or a long shot

Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022.

The spectacular success of cell therapies observed in heme tumors is not yet realized in solid tumors, however, stepped-up efforts to defeat unyielding tumor micro-environment and mechanisms of cell therapy dysfunction have started to bear fruits. Innovative approaches to engineer cell therapies from diverse immune cell sources e.g. adoptive TILs, CAR-T cells, TCR T cells, gamma delta T cells, NK cells, and macrophages have begun to show durable benefit. Early promise is noted in high unmet need, difficult to . . .

Access the full-content and exclusive insights by registering to futurebridge.com.

Benefits to Registered User on FutureBridge

Explore Key trends

Stay on top of your industry related trends and oppotunities.

Access to exclusive content

Get insightful information access without any restrictions.

Trending topics

Learn about fundamental challenges confronted by your industry.

Unrestricted webinar access

Gain access to all upcoming webinars and reply on-demand.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.

New Feature

Login with your mobile number. Update now.